Author

K. Porkka

h-index 63 View on Semantic Scholar

We have 3 of 447 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

SRSF2 mutations occur in 5-15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML pati...

S. Eldfors, Sumit Rai, Vineet Sharma et al. · Leukemia · 0 citations

#federated learning Open access Sep 2026

Federated learning in a regulator-audited secure processing environment: a multi-hospital deployment study

Background. Federated learning enables collaborative model development without transferring patient level data between institutions. However, translation into routine healthcare practice remains limited because deployment requires more than distributed model training. Federated infrastructures must operate within secur...

V. Nieminen, H. Schultze, S. Kukkurainen et al. · medRxiv · 0 citations

Open access Aug 2026

TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

The results suggest that anti-TIM3 combined with decitabine engages a distinct mechanism of immune activation compared to anti-PD1 and anti-CTLA4, preferentially expanding NK-cell and CD4+ T-cell populations.

Jani Huuhtanen, S. Forstén, B. Ford et al. · Cancer immunology research · 0 citations